Viatris (VTRS) Income towards Parent Company (2019 - 2026)

Viatris' (VTRS) quarterly Income towards Parent Company came in at $176.4 million in Q1 2026, up 105.8% year-on-year from $85.7 million in Q1 2025, and up 151.87% quarter-over-quarter from -$340.1 million in Q4 2025.

Viatris (VTRS) Income towards Parent Company (2019 - 2026) Analysis & Trends

Viatris' Income towards Parent Company history runs 8 years deep, the most recent figure standing at $176.4 million for Q1 2026.

  • On a quarterly basis, Income towards Parent Company rose 105.8% year-over-year to $176.4 million in Q1 2026; TTM through Mar 2026 was -$296.5 million, a 92.18% increase from a year earlier, with the FY2025 full-year figure at -$3.5 billion, down 454.23% from the prior year.
  • Income towards Parent Company grew to $176.4 million in Q1 2026 per VTRS's latest filing, from -$340.1 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $1.0 billion in Q4 2022 and bottomed at -$3.0 billion in Q1 2025.
  • The 5-year median for Income towards Parent Company is $113.9 million (2024), against an average of -$108.2 million.
  • Across the five-year window, Income towards Parent Company soared 483.32% in 2022 and slumped 2770.76% in 2025, its largest moves.
  • Year by year, Income towards Parent Company stood at $1.0 billion in 2022, then slumped by 175.71% to -$765.6 million in 2023, then jumped by 32.54% to -$516.5 million in 2024, then jumped by 34.15% to -$340.1 million in 2025, then jumped by 151.87% to $176.4 million in 2026.
  • Per Business Quant, the three latest VTRS Income towards Parent Company figures stand at $176.4 million (Q1 2026), -$340.1 million (Q4 2025), and -$128.2 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 88.07 Bn 86.20 Bn -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 176.40 Mn
Dec 31, 2025 -340.10 Mn
Sep 30, 2025 -128.20 Mn
Jun 30, 2025 -4.60 Mn
Mar 31, 2025 -3.04 Bn
Dec 31, 2024 -516.50 Mn
Sep 30, 2024 94.80 Mn
Jun 30, 2024 -326.40 Mn
Mar 31, 2024 113.90 Mn
Dec 31, 2023 -765.60 Mn
Sep 30, 2023 331.60 Mn
Jun 30, 2023 264.00 Mn
Mar 31, 2023 224.70 Mn
Dec 31, 2022 1.01 Bn
Sep 30, 2022 354.30 Mn
Jun 30, 2022 313.90 Mn
Mar 31, 2022 399.20 Mn
Dec 31, 2021 -263.80 Mn
Sep 30, 2021 311.50 Mn
Jun 30, 2021 -279.20 Mn